We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

35 hedge funds and large institutions have $3.77M invested in Navidea Biopharmaceuticals Inc. in 2021 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 13 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 4

11% more capital invested

Capital invested by funds: $3.4M → $3.77M (+$376K)

5% less call options, than puts

Call options by funds: $369K | Put options by funds: $390K

3% less funds holding

Funds holding: 36 → 35 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
35
Holders Change
-1
Holders Change %
-2.78%
% of All Funds
0.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
13
Reduced
4
Closed
3
Calls
$369K
Puts
$390K
Net Calls
-$21K
Net Calls Change
+$5K

Top Buyers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
+$216K
2
Renaissance Technologies
Renaissance Technologies
New York
+$178K
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$117K
4
Two Sigma Investments
Two Sigma Investments
New York
+$99.9K
5
Citadel Advisors
Citadel Advisors
Florida
+$87.1K

Top Sellers

Rank Fund Capital Flow
1
SFI
Susquehanna Fundamental Investments
Pennsylvania
-$71K
2
HighTower Advisors
HighTower Advisors
Illinois
-$48.2K
3
Simplex Trading
Simplex Trading
Illinois
-$27.5K
4
Wolverine Trading
Wolverine Trading
Illinois
-$9.66K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.51K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.47M – – –
BCM
2
Bridgeway Capital Management
Texas
$409K +$216K +92,500 +84%
Two Sigma Investments
3
Two Sigma Investments
New York
$292K +$99.9K +42,696 +42%
Renaissance Technologies
4
Renaissance Technologies
New York
$266K +$178K +75,923 +136%
BlackRock
5
BlackRock
New York
$265K +$1.02K +436 +0.3%
Two Sigma Advisers
6
Two Sigma Advisers
New York
$258K +$117K +50,000 +65%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$151K – – –
ACM
8
Allred Capital Management
Texas
$129K +$25.9K +11,077 +21%
Citadel Advisors
9
Citadel Advisors
Florida
$110K +$87.1K +37,219 +215%
Northern Trust
10
Northern Trust
Illinois
$80K +$1.41K +601 +2%
Group One Trading
11
Group One Trading
Illinois
$58K +$23K +9,846 +53%
Squarepoint
12
Squarepoint
New York
$58K +$67.5K +28,836 New
Morgan Stanley
13
Morgan Stanley
New York
$38K +$20.2K +8,633 +84%
California Public Employees Retirement System
14
California Public Employees Retirement System
California
$37K – – –
HighTower Advisors
15
HighTower Advisors
Illinois
$33K -$48.2K -20,600 -57%
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$25K -$2.51K -1,071 -8%
Wolverine Trading
17
Wolverine Trading
Illinois
$22K -$9.66K -4,128 -27%
PFO
18
Pathstone Family Office
New Jersey
$20K – – –
SFS
19
Sowell Financial Services
Arkansas
$18K – – –
Wells Fargo
20
Wells Fargo
California
$10K +$70 +30 +0.6%
UBS Group
21
UBS Group
Switzerland
$5K +$4.38K +1,870 +229%
Citigroup
22
Citigroup
New York
$4K – – –
Bank of America
23
Bank of America
North Carolina
$3K -$1.46K -625 -26%
JP Morgan Chase
24
JP Morgan Chase
New York
$3K – – –
JCM
25
Jacobi Capital Management
Pennsylvania
$2K – – –
1
2

NAVB Hedge Fund Activity: Q1 2021 in Review

35 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2021, worth a combined $3.77M — up 11% from $3.4M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of NAVB and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 13 added.

The largest buyer was Bridgeway Capital Management, adding an estimated $216K. The largest seller was Susquehanna Fundamental Investments, exiting entirely with an estimated $71K sold.

  • 35 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2021, down from 36 in Q4 2020.
  • Funds reported $3.77M of Navidea Biopharmaceuticals Inc. stock for Q1 2021, up 11% quarter-over-quarter.
  • 2 funds opened new Navidea Biopharmaceuticals Inc. positions in Q1 2021 and 3 closed out, a net change of -1 holder.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q1 2021 was Bridgeway Capital Management, an estimated $216K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q1 2021 was Susquehanna Fundamental Investments, an estimated $71K sold.

Based on aggregated 13F filings for Q1 2021.